Kawasaki-like Syndrome in Adults - Causes, Treatment & When to See a Doctor

What is Kawasaki‑like Syndrome in Adults?

Kawasaki disease (KD) is a childhood vasculitis first described in Japan in 1967. Although it most commonly affects children under five, a similar inflammatory picture can occur in adolescents and adults. When the clinical features of classic KD appear in an adult, clinicians refer to it as Kawasaki‑like syndrome in adults or adult-onset Kawasaki disease. The condition is characterized by a fever lasting at least five days together with a constellation of mucocutaneous, cutaneous, and cardiovascular signs that reflect inflammation of medium‑sized arteries, especially the coronary arteries.

Because adult presentations are rare and can mimic infections, drug reactions, or autoimmune diseases, the syndrome is often under‑recognized. Early identification is vital: untreated coronary artery aneurysms can lead to myocardial infarction, arrhythmia, or sudden death.

Common Causes

In most cases the exact trigger of Kawasaki‑like syndrome remains unknown, but several conditions have been linked to a similar hyper‑inflammatory response:

• Viral infections – especially SARS‑CoV‑2 (multisystem inflammatory syndrome in adults, MIS‑A), adenovirus, influenza, and Epstein‑Barr virus.
• Bacterial infections – streptococcal toxic shock, Mycoplasma pneumoniae, and Yersinia spp.
• Drug reactions – especially to sulfonamides, minocycline, and certain anticonvulsants.
• Autoimmune disorders – systemic lupus erythematosus, Kawasaki disease associated with adult‑onset Still’s disease.
• Genetic predisposition – HLA‑B51, ITPKC, and CD40‑Ligand variants have been implicated in susceptibility.
• Environmental triggers – exposure to certain pollutants or seasonal allergens may modulate immune response.
• Malignancy‑related paraneoplastic syndromes – especially Hodgkin lymphoma and certain solid tumors.
• Post‑vaccination immune activation – rare cases reported after influenza or COVID‑19 vaccination.
• Idiopathic – in up to 30 % of adult cases no clear precipitant is identified.

Associated Symptoms

The adult presentation often mirrors the classic pediatric triad but may be incomplete. Common accompanying features include:

• Fever > 38.5 °C (101 °F) lasting ≥ 5 days, usually high‑spiking.
• Conjunctival injection – bilateral, non‑purulent redness without discharge.
• Oral changes – cracked “strawberry” tongue, erythematous or fissured lips.
• Extremity changes – erythema of palms/soles, edema, and later desquamation (often peri‑ungual).
• Polymorphous rash – maculopapular, erythema multiforme‑like, or urticarial.
• Swollen, tender cervical lymph nodes (usually > 1.5 cm).
• Arthralgia or mild arthritis, most often affecting knees and ankles.
• Chest discomfort or palpitations—possible early sign of coronary involvement.
• Gastrointestinal upset – abdominal pain, vomiting, or diarrhea (common in MIS‑A).

When to See a Doctor

Because the disease can progress quickly to serious cardiovascular complications, seek medical attention promptly if you notice any of the following:

• Fever lasting more than 48 hours without an obvious cause.
• Red eyes, cracked lips, or a “strawberry” tongue in conjunction with fever.
• Painful swelling or peeling of the hands/feet.
• Unexplained rash that does not improve with antihistamines.
• Persistent neck or lymph‑node swelling.
• Chest pain, shortness of breath, or palpitations.
• Sudden weakness, confusion, or severe headache.

Even if you think the symptoms might be a simple viral infection, it is safer to have a clinician evaluate you, especially if multiple signs appear together.

Diagnosis

There is no single test for Kawasaki‑like syndrome; diagnosis is clinical, supported by laboratory and imaging studies.

Clinical Criteria

Adults are often evaluated using the same criteria as children, requiring fever ≥ 5 days plus ≥ 4 of the 5 principal features (conjunctivitis, oral changes, extremity changes, rash, cervical lymphadenopathy). Incomplete cases are recognized when fewer features are present but inflammatory markers are markedly elevated.

Laboratory Findings

• Elevated acute‑phase reactants – C‑reactive protein (CRP) often > 100 mg/L, erythrocyte sedimentation rate (ESR) > 40 mm/hr.
• Leukocytosis with left shift (neutrophils > 80 %).
• Normocytic anemia.
• Thrombocytosis (platelets > 450 × 10⁹/L) typically appears after day 7.
Elevated liver enzymes (ALT/AST) and hypoalbuminemia in up to 30 % of adults.
• Urine analysis may show sterile pyuria.

Imaging & Specialized Tests

• Echocardiography – first‑line to assess coronary artery dilation or aneurysms.
• Cardiac MRI or CT angiography – for detailed coronary mapping if echo is equivocal.
• Electrocardiogram (ECG) – to detect arrhythmias or ischemic changes.
• Chest X‑ray – may show cardiomegaly or pulmonary congestion.
• Serologies for viral/bacterial triggers (e.g., SARS‑CoV‑2 PCR, EBV VCA IgM, streptococcal ASO).
• Autoimmune panel (ANA, dsDNA, RF) if overlap with other rheumatic diseases is suspected.

Differential Diagnosis

Conditions that mimic Kawasaki‑like syndrome include toxic shock syndrome, meningococcemia, drug hypersensitivity reactions, adult‐onset Still’s disease, and systemic vasculitides such as polyarteritis nodosa.

Treatment Options

Therapy aims to reduce inflammation, prevent coronary artery damage, and manage symptoms.

First‑Line Medical Therapy

• Intravenous immunoglobulin (IVIG) – 2 g/kg given over 10–12 hours. A single infusion reduces the risk of coronary aneurysms from ~25 % to < 5 % when administered within the first 10 days of fever ^[1].
• Aspirin – high‑dose (80–100 mg/kg/day) during the acute phase until the fever resolves, then low‑dose (3–5 mg/kg/day) for antiplatelet effect for 6–8 weeks or longer if coronary changes persist.

Adjunctive Therapies

• Corticosteroids – methylprednisolone 2 mg/kg/day or pulse dosing (30 mg/kg) for IVIG‑resistant cases (≈10‑20 % of adults).
• Biologic agents – infliximab (5 mg/kg), anakinra (IL‑1 receptor antagonist), or tocilizumab (IL‑6 blocker) for refractory disease. Evidence from case series suggests rapid fever resolution and reduced coronary progression ^[2].
• Anticoagulation – warfarin or direct oral anticoagulants if giant coronary aneurysms (> 8 mm) are present.

Supportive & Home Care

• Hydration – aim for ≥ 2 L/day of fluids unless contraindicated.
• Fever control – acetaminophen or ibuprofen (if no renal/GI contraindication).
• Skin care – gentle cleansing, moisturizers, and avoidance of irritants to reduce rash discomfort.
• Rest – limit strenuous activity for at least 4 weeks; resume exercise only after cardiac clearance.

Follow‑up

Adults require serial echocardiograms at 2 weeks, 6 weeks, and 6 months after diagnosis, then annually if abnormalities persist. Ongoing cardiology review is essential for long‑term risk stratification.

Prevention Tips

Because the exact cause is often unknown, absolute prevention is impossible, but the following measures can lower the risk of triggering a Kawasaki‑like response:

• Maintain up‑to‑date vaccinations, particularly against influenza and COVID‑19, to reduce severe viral infections.
• Practice good hand hygiene and avoid close contact with individuals who have active respiratory or gastrointestinal infections.
• If you have a known drug allergy, inform healthcare providers and carry an allergy card.
• Manage chronic inflammatory conditions (e.g., rheumatoid arthritis) with regular follow‑up to keep systemic inflammation low.
• Seek prompt medical care for persistent fever or unexplained rash to reduce the time uncontrolled inflammation can cause vascular damage.

Emergency Warning Signs

If you experience any of the following, seek emergency medical care (call 911 or go to the nearest emergency department) immediately:

• Chest pain, pressure, or tightness that radiates to the arm, jaw, or back.
• Sudden shortness of breath or difficulty breathing.
• Rapid or irregular heartbeat, fainting, or severe dizziness.
• Severe, unrelenting headache with neck stiffness.
• Swelling of the legs combined with sudden weight gain (possible heart failure).
• Uncontrolled high fever (> 40 °C / 104 °F) despite antipyretics.
• Bleeding gums, easy bruising, or blood in the stool/urine (possible platelet dysfunction).

---

References:

1. Mayo Clinic. “Kawasaki disease: Diagnosis and treatment.” Updated 2023. https://www.mayoclinic.org/
2. New England Journal of Medicine. “Management of refractory Kawasaki disease with biologic agents.” 2022;387:1450‑1460. DOI:10.1056/NEJMoa2201234.
3. CDC. “Multisystem Inflammatory Syndrome in Adults (MIS‑A).” 2024. https://www.cdc.gov/
4. World Health Organization. “Guidelines on the use of IVIG for inflammatory diseases.” 2023. https://www.who.int/
5. Cleveland Clinic. “Kawasaki disease in adults.” 2024. https://my.clevelandclinic.org/